

SUPPLEMENTAL MATERIAL

Direct oral anticoagulants in treatment of cerebral venous thrombosis: systematic review

Gauruv Bose¹, Justin Graveline¹, Vignan Yogendrakumar¹, Risa Shorr¹, Dean Fergusson¹, Gregoire Le Gal¹, Jonathan M. Coutinho², Marcelo Mendonça³, Miguel Viana-Baptista³, Simon Nagel⁴, and Dar Dowlatshahi¹

1. Department of Medicine, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, Canada
2. Department of Neurology, University Medical Center, Amsterdam, Netherlands
3. Department of Neurology, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal
4. Department of Neurology, University Hospital, University of Heidelberg, Heidelberg, Germany

Appendix III: Risk of Bias Tables

Table s1: Randomized Controlled Trials; Cochrane Risk of Bias Tool

	Year	Random Sequence Generation	Allocation Concealment	Blinding of Participants	Blinding of Outcome Assessment	Incomplete Outcome Data	Selective Reporting	Other Bias
Ferro et al[3]	2019	Low Risk: Patients were randomized using an online 24-hour telephone service	Low Risk: Concealment maintained using the telephone service	High Risk: Patients and treating teams were aware of treatment allocation.	Low Risk: All outcomes were adjudicated in a blinded manner by an adjudication committee	Low Risk: All missing/excluded patients were disclosed by study authors. Reasons for exclusion were provided. 11 patients lost to follow-up overall.	Low Risk all outcomes that were pre-specified were reported	Unclear exploratory trial with no formal hypothesis statistical testing

Appendix III: Risk of Bias Tables

Table s2: Observational Cohorts; NewCastle Ottawa Scale

	Year	Selection (Max☆☆☆☆)				Comparability (Max☆☆)	Outcome Max☆☆☆		
		Representativeness of the exposed cohort	Selection of the non- exposed cohort	Ascertainment of exposure	Outcome absent at study start	Comparable cohorts (design or analysis)	Assessment of outcome	Appropriate follow-up time	Adequate follow- up of cohorts
Hsu et al.[4]	2020	☆	☆	☆	☆		☆	☆	☆
Powell et al.[5]	2020	☆	☆	☆	☆		☆	☆	☆
Lurkin et al.[6]	2019	☆	☆	☆	☆		☆	☆	☆
Wasay et al.[7]	2019	☆	☆	☆	☆		☆	☆	☆
Herweh et al.[8] ^a	2016	☆	☆	☆	☆		☆	☆	☆
A. Additional patient level information was provided upon request to authors.									

Appendix III: Risk of Bias Tables

Table s3: Case Series; Johanna Briggs Institute Critical Appraisal for Case Series

	Year	Clear Inclusion Criteria	Condition Measured in Reliable Way	Valid Method to ID condition	Consecutive Inclusion	Complete Inclusion	Demographics	Clinical Information	Outcomes	Presenting Site, Clinical Demographics	Stat Analysis
Covut et al.[9]	2019	Y	N	N	Y	Y	Y	Y	Y	N	N
Rusin et al.[10]	2019	Y	Y	Y	Y	Y	Y	Y	Y	Y	N
Shankar Iyer et al.[11]	2018	Y	Unclear	Unclear	Y	Y	Y	Y	Y	N	N
Cappellari et a[12]	2017	Y	Unclear	Unclear	Unclear	Unclear	Y	Y	Y	N	Y
Anticoli et al. [13]	2016	Y	Y	Y	Y	Y	Y	Y	Y	Y	N
Mendonca et a[14]	2015	Y	Y	Y	Y	Y	Y	Y	Y	Y	N

Appendix III: Risk of Bias Tables

Table s4: Case Reports; Johanna Briggs Institute Critical Appraisal

	Year	Patient Demographics Clearly Described	Patient History Clearly Described	Clinical Condition Clearly Described	Diagnostic Tests Well Described	Intervention or Treatment Well Described	Post-Intervention Clinical Condition Described	Adverse Events	Takeaway Lesson?
Bando et al[15]	2020	Y	Y	Y	Y	Y	Y	N	Y
Saito et al[16]	2020	Y	N	Y	Y	N	Y	N	Y
Sugiyama et al[17]	2020	Y	N	Y	Y	Y	Y	Y	Y
Chiu et al[18]	2020	Y	N	Y	Y	N	Y	Y	Y
Bolaji et al[19]	2020	Y	Y	Y	Y	N	N	N	N
Huang et al[20]	2019	N	Y	Y	Y	Y	Y	Y	Y
Hu et al[21]	2019	Y	Y	Y	Y	Y	Y	N	Y
Yasushi [22]	2017	Y	Y	Y	Y	Y	Y	N	Y
Sui et al[23]	2017	N	Y	Y	Y	Y	Y	N	Y
Becerra et al[24]	2017	N	Y	Y	Y	Y	Y	Y	Y
Budhram et al[25]	2017	Y	Y	Y	Y	Y	N	N	Y
Hsu et al[26]	2017	N	Y	Y	Y	Y	Y	N	Y
Inche Mat et al[27]	2017	Y	N	Y	N	Y	N	N	Y
Rao et al[28]	2017	N	Y	Y	Y	Y	Y	N	Y
Talamo et al[29]	2017	Y	Y	Y	Y	Y	Y	N	Y
Cho et al[30]	2016	Y	Y	Y	Y	Y	Y	N	Y
Mieli et al[31]	2016	Y	Y	N	Y	N	Y	N	N
Mutgi et al[32]	2015	N	N	N	Y	N	Y	N	Y
Sugie et al[33]	2015	Y	Y	Y	Y	Y	Y	N	Y
Mathew et al[34]	2013	N	Y	Y	Y	Y	Y	N	Y
Hon et al[35]	2012	Y	Y	Y	Y	Y	Y	N	Y

Supplemental references

- 1 Bose G, Graveline J, Yogendrakumar V, et al Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol. *Syst Rev* 2019;**8**:99. doi:10.1186/s13643-019-1022-8
- 2 Bose G, Graveline J, Dowlatshahi D. Systematic review of direct oral anticoagulants in treatment of cerebral venous thrombosis. *PROSPERO* 2017.
- 3 Ferro JM, Coutinho JM, Dentali F, et al Safety and Efficacy of Dabigatran Etxilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis. *JAMA Neurol* Published Online First: 3 September 2019. doi:10.1001/jamaneurol.2019.2764
- 4 Hsu A, Mistry H, Lala N, et al Preliminary findings regarding the use of direct oral anticoagulants in cerebral venous thrombosis. *Clin Neurol Neurosurg* 2020;**198**:106204. doi:10.1016/j.clineuro.2020.106204
- 5 Powell M, Tremolet de Villers K, Schwarz K, et al A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis. *Ann Pharmacother* 2020;:106002802095274. doi:10.1177/1060028020952749
- 6 Lurkin A, Derex L, Fambrini A, et al Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis. *Cerebrovasc Dis* 2019;**48**:32–7. doi:10.1159/000502454
- 7 Wasay M, Khan M, Rajput HM, et al New Oral Anticoagulants versus Warfarin for Cerebral Venous Thrombosis: A Multi-Center, Observational Study. *J Stroke* 2019;**21**:220–3. doi:10.5853/jos.2019.00150
- 8 Herweh C, Griebe M, Geisbüsch C, et al Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis. *Eur J Neurol* 2016;**23**:681–7. doi:10.1111/ene.12901
- 9 Covut F, Kewan T, Perez O, et al Apixaban and rivaroxaban in patients with cerebral venous thrombosis. *Thromb Res* 2018;**173**:7–8. doi:10.1016/j.thromres.2018.11.018
- 10 Rusin G, Wypasek E, Papuga-Szela E, et al Direct oral anticoagulants in the treatment of cerebral venous sinus thrombosis: a single institution's experience. *Neurol Neurochir* 2019;**53**:384–387. doi:10.5603/PJNNS.a2019.0037
- 11 Shankar Iyer R, TCR R, Akhtar S, et al Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients. *Clin Neurol Neurosurg* 2018;**175**:108–11. doi:10.1016/j.clineuro.2018.10.015
- 12 Cappellari M, Bovi P. Direct oral anticoagulants in patients with cervical artery dissection and cerebral venous thrombosis. A case series and review of the

- Successful Use of DOAC in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): A Case Report. *J Stroke Cerebrovasc Dis*; **29**:105261. doi:10.1016/j.jstrokecerebrovasdis.2020.105261
- 16 Saito K, Ishii K, Furuta K, et al Recurrent Cerebral Venous Thrombosis Treated with Direct Oral Anticoagulants in a Japanese Man with Hereditary Protein C Deficiency. *J Stroke Cerebrovasc Dis*; **29**:105320. doi:10.1016/j.jstrokecerebrovasdis.2020.105320
- 17 Sugiyama Y, Tsuchiya T, Tanaka R, et al Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report. *J Clin Neurosci*; **2020**; **79**:30–2. doi:10.1016/j.jocn.2020.07.038
- 18 Chiu D, Weinberger J. Cerebral Venous Sinus Thrombosis and Acute Myocardial Infarction in a Patient with PAI-1 4G/4G Homozygosity. *J Stroke Cerebrovasc Dis* **2020**; **29**:105250. doi:10.1016/j.jstrokecerebrovasdis.2020.105250
- 19 Bolaji P, Kukoyi B, Ahmad N, et al Extensive cerebral venous sinus thrombosis: a potential complication in a patient with COVID-19 disease. *BMJ Case Rep* **2020**; **13**:e236820. doi:10.1136/bcr-2020-236820
- 20 Huang Q, Chai X, Xiao C, et al A case report of oral contraceptive misuse induced cerebral venous sinus thrombosis and dural arteriovenous fistula. *Medicine (Baltimore)*; **2019**; **98**:e16440. doi:10.1097/MD.00000000000016440
- 21 Hu Y, Tang Z, Zhu W, et al Clinical Reasoning: A teenager with persistent headache. *Neurology*; **2019**; **92**:e1526–31. doi:10.1212/WNL.00000000000007184
- 22 Yasushi S. Successful Treatment of Cerebral Sinus Thrombosis with Edoxaban Alone. *Int J Crit Care Emerg Med*; **2017**; **3**. doi:10.23937/2474-3674/1510029
- 23 Sui J, Zhang Y, Yang L, et al Successful treatment with rivaroxaban of cerebral venous thrombosis and bone marrow necrosis induced by pegaspargase: A case report and literature review. *Medicine (Baltimore)*; **2017**; **96**:e8715. doi:10.1097/MD.00000000000008715
- 24 Becerra AF, Amuchastegui T, Tabares AH. Decreased Rivaroxaban Levels in a Patient with Cerebral Vein Thrombosis Receiving Phenytoin. *Case Rep Hematol* **2017**; **2017**:3. doi:10.1155/2017/4760612
- 25 Budhram A, Shettar B, Lee DH, et al Bilateral Cavernous Sinus Thrombosis in Lemierre's Syndrome. *Can J Neurol Sci / J Can des Sci Neuro*; **2016**; **44**:424–6. doi:10.1017/cjn.2016.438
- 26 Hsu Y, Juan C, Le J, et al Anti-N-methyl-D-aspartate-receptor encephalitis complicated with antiphospholipid syndrome and cerebral venous thrombosis. *J Clin Rheumatol*; **2017**; **23**:294–5. doi:10.1186/2047-2994-1-19.
- 27 Inche Mat LN, Wan Sulaiman WA, Hoo FK, et al A rare case of vein of Galen thrombosis: Exploring a potential role for novel oral anticoagulants (NOACs) in cerebral deep vein thrombosis. *Rawal Med. J.* **2017**; **42**:432–4.

- 30 Cho Y, Chae MK, Cha JM, et al Cerebral venous thrombosis in a patient with Crohn's disease. *Intest Res* 2016;**14**:96. doi:10.5217/ir.2016.14.1.96
- 31 Micieli JA, Derkatch S, Pereira VM, et al Development of dural arteriovenous fistulas after cerebral venous sinus thrombosis. *J Neuro-Ophthalmology* 2016;**36**:53–7. doi:10.1097/WNO.0000000000000288
- 32 Mutgi SA, Grose NA, Behrouz R. Rivaroxaban for the treatment of cerebral venous thrombosis. *Int J Stroke* 2015;**10**:167–8. doi:10.1111/ijs.12592
- 33 Sugie M, Iizuka N, Shimizu Y, et al Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid. *Intern Med* 2015;**54**:3051–6. doi:10.2169/internalmedicine.54.5045
- 34 Mathew T, Lobo A, Kukkuta Sarma G, et al A case of post varicella cortical venous thrombosis successfully treated with dabigatran. *Neurol India* 2013;**61**:531. doi:10.4103/0028-3886.121939
- 35 Hon SFK, Li HLT, Cheng PW. Use of direct thrombin inhibitor for treatment of cerebral venous thrombosis. *J Stroke Cerebrovasc Dis* 2012;**21**:915.e11-915.e15. doi:10.1016/j.jstrokecerebrovasdis.2012.02.004